Fixed combination of highly selective β-adrenoblocker bisoprolol and calcium antagonist amlodipine (Concor® AM) for arterial hypertension treatment in metabolic disorder patients
Introduction. Combination therapy is widely used in treatment of patients with arterial hypertension (AH) of high and very high cardiovascular risk. Fixed combinations (FC) of medications are preferable and it is important to develop new effective and safe ones. Organ-protective effects are also sig...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IP Morozov P.V.
2017-02-01
|
| Series: | Системные гипертензии |
| Subjects: | |
| Online Access: | http://syst-hypertension.ru/en/archive/2017/vol-14-1-2017/fixed-combination-of-highly-selective-adrenoblocker-bisoprolol-and-calcium-antagonist-amlodipine-con_1796/ |
| _version_ | 1811285955263332352 |
|---|---|
| author | Zhernakova Yu.V. Martyniuk T.V. Arkhipova O.A. |
| author_facet | Zhernakova Yu.V. Martyniuk T.V. Arkhipova O.A. |
| author_sort | Zhernakova Yu.V. |
| collection | DOAJ |
| description | Introduction. Combination therapy is widely used in treatment of patients with arterial hypertension (AH) of high and very high cardiovascular risk. Fixed combinations (FC) of medications are preferable and it is important to develop new effective and safe ones. Organ-protective effects are also significant.
Objective. To study antihypertensive effectiveness of new FC of highly selective β-adrenoblocker bisoprolol and calcium antagonist amlodipine (Concor® AM), its influence on cardiometabolic risk factors and target lesions in metabolic disorder patients with AH of stages 1 or 2.
Materials and methods. The study included 30 patients (13 male, 17 female, mean age 47.20±0.22 years) with AH of stages 1 or 2 and metabolic syndrome (MS). All patients underwent clinical assessment of blood pressure (BP); levels of serum cholesterol (SCL), high density lipoprotein (HDL), low density lipoprotein (LDL), triglyceride, creatinine, and glucose in oral glucose tolerance test; 24-hour blood pressure monitoring; central systolic blood pressure (CSBP); carotid-femoral pulse wave velocity (cfPWV), and intima-media complex thickness which were determined initially and after 6 months of therapy with FC.
Results. The target level of BP was reached by 88% patients after treatment with Concor® AM.
Significant deceleration of heart rate (from 74.95±2.20 to 68.81±1.13 bpm) and CSBP (from 151.7 до 132.6 mm Hg) were observed. Treatment with Concor® AM led to artery stiffness decrease evaluated by cfPWV decrease (from 14.21±0.45 to 12.1±0.23 m/s, p≤0.05).
Conclusion. FC of highly selective β-adrenoblocker bisoprolol and calcium antagonist amlodipine (Concor® AM) was shown effective for AH treatment in patients with MS. Future research is recommended to investigate the effectiveness of FC therapy in a larger cohort of patients. |
| first_indexed | 2024-04-13T02:51:38Z |
| format | Article |
| id | doaj.art-cdcb89345a25406f82e75ae9fe024fb3 |
| institution | Directory Open Access Journal |
| issn | 2075-082X 2542-2189 |
| language | Russian |
| last_indexed | 2024-04-13T02:51:38Z |
| publishDate | 2017-02-01 |
| publisher | IP Morozov P.V. |
| record_format | Article |
| series | Системные гипертензии |
| spelling | doaj.art-cdcb89345a25406f82e75ae9fe024fb32022-12-22T03:05:49ZrusIP Morozov P.V.Системные гипертензии2075-082X2542-21892017-02-01141455010.26442/2075-082X_14.1.45-50Fixed combination of highly selective β-adrenoblocker bisoprolol and calcium antagonist amlodipine (Concor® AM) for arterial hypertension treatment in metabolic disorder patientsZhernakova Yu.V.0Martyniuk T.V.1Arkhipova O.A.2A.L.Myasnikov Institute of Clinical Cardiology Russian Cardiological Scientific-Industrial Complex of the Ministry of Health of the Russian Federation. 121552, Russian Federation, Moscow, ul. 3-ia Cherepkovskaia, d. 15aA.L.Myasnikov Institute of Clinical Cardiology Russian Cardiological Scientific-Industrial Complex of the Ministry of Health of the Russian Federation. 121552, Russian Federation, Moscow, ul. 3-ia Cherepkovskaia, d. 15aA.L.Myasnikov Institute of Clinical Cardiology Russian Cardiological Scientific-Industrial Complex of the Ministry of Health of the Russian Federation. 121552, Russian Federation, Moscow, ul. 3-ia Cherepkovskaia, d. 15aIntroduction. Combination therapy is widely used in treatment of patients with arterial hypertension (AH) of high and very high cardiovascular risk. Fixed combinations (FC) of medications are preferable and it is important to develop new effective and safe ones. Organ-protective effects are also significant. Objective. To study antihypertensive effectiveness of new FC of highly selective β-adrenoblocker bisoprolol and calcium antagonist amlodipine (Concor® AM), its influence on cardiometabolic risk factors and target lesions in metabolic disorder patients with AH of stages 1 or 2. Materials and methods. The study included 30 patients (13 male, 17 female, mean age 47.20±0.22 years) with AH of stages 1 or 2 and metabolic syndrome (MS). All patients underwent clinical assessment of blood pressure (BP); levels of serum cholesterol (SCL), high density lipoprotein (HDL), low density lipoprotein (LDL), triglyceride, creatinine, and glucose in oral glucose tolerance test; 24-hour blood pressure monitoring; central systolic blood pressure (CSBP); carotid-femoral pulse wave velocity (cfPWV), and intima-media complex thickness which were determined initially and after 6 months of therapy with FC. Results. The target level of BP was reached by 88% patients after treatment with Concor® AM. Significant deceleration of heart rate (from 74.95±2.20 to 68.81±1.13 bpm) and CSBP (from 151.7 до 132.6 mm Hg) were observed. Treatment with Concor® AM led to artery stiffness decrease evaluated by cfPWV decrease (from 14.21±0.45 to 12.1±0.23 m/s, p≤0.05). Conclusion. FC of highly selective β-adrenoblocker bisoprolol and calcium antagonist amlodipine (Concor® AM) was shown effective for AH treatment in patients with MS. Future research is recommended to investigate the effectiveness of FC therapy in a larger cohort of patients.http://syst-hypertension.ru/en/archive/2017/vol-14-1-2017/fixed-combination-of-highly-selective-adrenoblocker-bisoprolol-and-calcium-antagonist-amlodipine-con_1796/arterial hypertensionmetabolic syndromeantihypertensive therapycombined therapy |
| spellingShingle | Zhernakova Yu.V. Martyniuk T.V. Arkhipova O.A. Fixed combination of highly selective β-adrenoblocker bisoprolol and calcium antagonist amlodipine (Concor® AM) for arterial hypertension treatment in metabolic disorder patients Системные гипертензии arterial hypertension metabolic syndrome antihypertensive therapy combined therapy |
| title | Fixed combination of highly selective β-adrenoblocker bisoprolol and calcium antagonist amlodipine (Concor® AM) for arterial hypertension treatment in metabolic disorder patients |
| title_full | Fixed combination of highly selective β-adrenoblocker bisoprolol and calcium antagonist amlodipine (Concor® AM) for arterial hypertension treatment in metabolic disorder patients |
| title_fullStr | Fixed combination of highly selective β-adrenoblocker bisoprolol and calcium antagonist amlodipine (Concor® AM) for arterial hypertension treatment in metabolic disorder patients |
| title_full_unstemmed | Fixed combination of highly selective β-adrenoblocker bisoprolol and calcium antagonist amlodipine (Concor® AM) for arterial hypertension treatment in metabolic disorder patients |
| title_short | Fixed combination of highly selective β-adrenoblocker bisoprolol and calcium antagonist amlodipine (Concor® AM) for arterial hypertension treatment in metabolic disorder patients |
| title_sort | fixed combination of highly selective β adrenoblocker bisoprolol and calcium antagonist amlodipine concor r am for arterial hypertension treatment in metabolic disorder patients |
| topic | arterial hypertension metabolic syndrome antihypertensive therapy combined therapy |
| url | http://syst-hypertension.ru/en/archive/2017/vol-14-1-2017/fixed-combination-of-highly-selective-adrenoblocker-bisoprolol-and-calcium-antagonist-amlodipine-con_1796/ |
| work_keys_str_mv | AT zhernakovayuv fixedcombinationofhighlyselectivebadrenoblockerbisoprololandcalciumantagonistamlodipineconcoramforarterialhypertensiontreatmentinmetabolicdisorderpatients AT martyniuktv fixedcombinationofhighlyselectivebadrenoblockerbisoprololandcalciumantagonistamlodipineconcoramforarterialhypertensiontreatmentinmetabolicdisorderpatients AT arkhipovaoa fixedcombinationofhighlyselectivebadrenoblockerbisoprololandcalciumantagonistamlodipineconcoramforarterialhypertensiontreatmentinmetabolicdisorderpatients |